ArticleThoracic cancer2023

The survival after discontinuation of EGFR-TKIs due to intolerable adverse events in patients with EGFR-mutated non-small cell lung cancer.

John Wen-Cheng Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.